Supporting The Front Line of Our Freedom January 8, 2016 • admin • Working to better protect our military personnel from chemical nerve agent attack. Related News Countervail receives $981,000 SBIR Fast Track Phase II grant award for continued development of AverTox® (galantamine) for pre-exposure administration to protect against soman toxicity. December 7, 2013 Countervail Corporation is awarded a $5.3 million contract by the Biomedical Advanced Research and Development Authority September 15, 2011
